American Diabetes Association

Economic costs of diabetes in the U.S. in 2017.

Diabetes Care. 41: 917-928

The cost of diabetes in Canada over 10 years: applying attributable health care costs to a diabetes incidence prediction model.

Health Promot Chronic Dis Prev Can. 37: 49-53Zhou X Shrestha SS Shao H Zhang P

Factors contributing to the rising national cost of glucose-lowering medicines for diabetes during 2005-2007 and 2015-2017.

Diabetes Care. 43: 2396-2402Hua X Carvalho N Tew M Huang ES Herman WH Clarke P.

Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013.

JAMA. 315: 1400

Patented Medicine Prices Review Board. Potential savings from biosimilars in Canada. 2017. http://pmprb-cepmb.gc.ca. Accessed March 9, 2021.

CADTH Therapeutic Review. New drugs for type 2 diabetes: second-line therapy – science report. 2017. https://cadth.ca/drugs-type-2-diabetes-second-line-therapy-review-update. Accessed August 26, 2021.

Berger J. Biologics in Canada, part 1: market trends, 2018 (table 2.1). 2020. https://www.canada.ca/en/patented-medicine-prices-review/services/reports-studies/biologics-part1-market-trends.html. Accessed January 4, 2021.

Bly CA Gahn JC Wielage RC Klein RW Brown K Kalirai S.

Budget impact analysis of basaglar for the treatment of type 1 and type 2 diabetes in patients eligible for a long-acting insulin analog.

Value Health. 21: S72-S73Mehring M Heim A Peyrol C et al.

Implementation of biosimilar uptake: a cost minimization study for insulin glargine.

Int J Clin Pharm. 41: 372Mansell K Bhimji H Eurich D Mansell H.

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.

BMC Health Serv Res. 19: 827-828Weise M Bielsky M De Smet K et al.

Biosimilars-why terminology matters.

Nat Biotechnol. 29: 690-693Barbier L Ebbers HC Declerck P Simoens S Vulto AG Huys I.

The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review.

Clin Pharmacol Ther. 108: 734-755Tieu C Lucas EJ DePaola M Rosman L Alexander GC.

Efficacy and safety of biosimilar insulins compared to their reference products: a systematic review.

PLoS ONE. 13e0195012DeLozier AM Ilag LL PerezNieves M et al.

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2.

GaBI J. 7: 6Maes ML Ashjian EJ Kippes KA Marshall V Rida N Thompson AN.

Impact of dosing conversion from basal insulin to follow-on insulin glargine.

J Pharm Pract. 34: 183-189Pitlick JM Bryant GA Daly MW et al.

Real-world evaluation of dosing in patients converted from insulin glargine (Lantus) to insulin glargine (Basaglar).

Ann Pharmacother. 54: 846-851Shingaki T Taki K Koyanagi M et al.

Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.

Curr Med Res Opin. 36: 947-958Taki K Koyanagi M Nagaoka S Shingaki T.

Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.

Curr Med Res Opin. 36: 1975-1983

Insulin glargine and hypersensitivity reactions as an example of biosimilars pharmacovigilance.

Pharmacoepidemiol Drug Saf. 29: 22Halimi V Daci A Ancevska Netkovska K Suturkova L Babar Z Grozdanova A

Clinical and regulatory concerns of biosimilars: a review of literature.

Int J Environ Res Public Health. 17: 5800

Accessed March 5, 2021.

Hernandez I Good CB Shrank WH Gellad WF.

Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018.

JAMA. 321: 1627-1629

British Columbia Ministry of Health ǀ PharmaCare. Limited coverage drug (LCD) program. 2021. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/limited-coverage-drug-program. Accessed December 21, 2021.

British Columbia Ministry of Health ǀ PharmaCare. Biosimilars initiative insulin glargine. https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/patient-info-insulin-glargine_final.pdf. Accessed October 19, 2021.

British Columbia Ministry of Health. Fair PharmaCare plan. https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/who-we-cover/fair-pharmacare-plan. Accessed August 12 2021.

Health Canada. Canada's health care system. 2011. https://www.canada.ca/en/health-canada/services/health-care-system/reports-publications/health-care-system/canada.html#a5. Accessed January 25, 2021.

First Nations Health Authority. Benefits. https://www.fnha.ca/benefits. Accessed August 11, 2021.

British Columbia Ministry of Health ǀ PharmaCare. What is a deductible? in fair PharmaCare plan https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/who-we-cover/fair-pharmacare-plan. Accessed March 9, 2021.

Lo-Ciganic W Zgibor JC Ruppert K Arena VC Stone RA.

Identifying type 1 and type 2 diabetic cases using administrative data: a tree-structured model.

J Diabetes Sci Technol. 5: 486-493Charlson ME Pompei P Ales KL MacKenzie CR.

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

J Chronic Dis. 40: 373-383Ranganathan P Pramesh CS Buyse M.

Common pitfalls in statistical analysis: the perils of multiple testing.

Perspect Clin Res. 7: 106-107

A Likelihood Paradigm.

Chapman & Hall, New York, NY

P values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate.

Am J Epidemiol. 137: 485-496Dormuth CR Fisher A Carney G.

A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.

Pharmacoepidemiol Drug Saf. 29: 796-802Fisher A Kim JD Dormuth CR.

Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-an interim report.

Pharmacoepidemiol Drug Saf. 29: 803-810Blevins TC Barve A Raiter Y et al.

Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: results of the INSTRIDE 3 phase 3 switch study.

Diabetes Obes Metab. 22: 365-372Hu X Zhang L Dong Y Dong C Jiang J Gao W.

Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review [version 1; peer review: 3 approved, 1 approved with reservations].

F1000 Res. 7: 477Fleischmann R Jairath V Mysler E Nicholls D Declerck P.

Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?.

Rheumatol Ther. 7: 35-64Moura CS Choquette D Coupal L et al.

Persistence in rheumatoid arthritis patients on biosimilar and bio-originator etanercept: a pooled analysis of Pancanadian cohorts.

ARD. 79: 306-307Clement J Jacobi M Greenwood BN.

Patient access to chronic medications during the covid-19 pandemic: evidence from a comprehensive dataset of US insurance claims.

PLoS ONE. 16e0249453American Diabetes Associate

Standards of medical care in diabetes-2019 abridged for primary care providers.

Clin Diabetes. 37: 11-34

British Columbia Ministry of Health ǀ PharmaCare. PharmaCare newsletter, edition 19-003. 2019. https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/newsletters/news19-003.pdf. Accessed June 8, 2021.

Glintborg B Ibsen R Bilbo REQ Lund Hetland M Kjellberg J

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? a Danish register-based study of patients with inflammatory arthritis.

RMD Open. 5e001016Convertino I Lucenteforte E Gini R et al.

Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons.

Clin Exp Rheumatol. 39: 753-762Phillips K Juday T Zhang Q Keshishian A.

Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or CT-p13 in the Turkish population.

ARD. 76: 835